Year: 2019

REHOVOT, Israel, Dec. 06, 2019 (GLOBE NEWSWIRE) — Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer’s disease, today announced that Todos Medical will be presenting at the upcoming LD Micro International Annual Invitational on Tuesday, December 10th, in Bel-Air, California.The following are details for the conferences:Event: 12th Annual LD Micro Main EventDates: Dec 10 – 12, 2019Location: Luxe Sunset, Bel-Air, CATodos Medical will be presenting on Tuesday, December 10th, at 3:40pm PSTThe micro-cap conference is dedicated to connecting small and micro-cap companies with high-level, institutional and retail investors. Additionally, this event presents an opportunity...

Oboya Horticulture Industries AB: s (” Oboya” eller” Bolaget”) företrädesemission har registrerats vid Bolagsverket. Sista dag för handel i Bolagets betalda tecknade aktier, OBOYA BTA B, är den 11 december 2019. Stoppdag hos Euroclear för växling från BTA till aktier är den 13 december 2019. De nya aktierna beräknas bokas ut på respektive aktieägares VP-konto/depå den 17 december 2019.Efter registrering av företrädesemissionen och den kvittningsemission som offentliggjordes den 25 november 2019 uppgår Oboyas aktiekapital till 1 256 175,08 SEK och antalet B-aktier till 34 485 918.RådgivareAugment Partners AB är finansiell rådgivare och Hamilton Advokatbyrå KB är legal rådgivare till Oboya i samband med Företrädesemissionen. Aqurat Fondkommission AB agerar emissionsinstitut.För mer information, vänligen kontakta:Robert Wu, VD Oboya Horticulture...

MEDDELELSE NR. 181 Der er indgået aftale om, at ChemoMetecs nye CEO Steen Søndergaard tiltræder den 2. januar 2020.I en tidligere meddelelse, offentliggjort den 1. december 2019, blev det meddelt, at Steen Søndergaard hurtigst muligt ville tiltræde som CEO i ChemoMetec.Bestyrelsesformand i ChemoMetec, Preben Kønig, udtaler i forbindelse med Steen Søndergaards tiltræden: ”Vi er glade for, at Steen Søndergaard kan tiltræde allerede lige efter nytår og ser frem til at byde ham velkommen i ChemoMetec. Steen Søndergaard har via sin tidligere ansættelse et godt forudgående kendskab til ChemoMetec, herunder til vores kunder, produkter og markeder. Samtidig har ham mere end 25 års erfaring som leder inden for teknologi- og medicoindustrien, så jeg er sikker på, at vi med Steen Søndergaard i spidsen for ChemoMetec kan videreføre de seneste års...

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preliminary safety and efficacy data from an investigator-sponsored trial evaluating telaglenastat (CB-839) in combination with azacitidine will be presented in an oral session at the American Society of Hematology (ASH) Annual Meeting 2019 taking place December 7-10, in Orlando, Florida.“Telaglenastat is being evaluated in multiple tumor types through investigator-sponsored trials, and we are excited to see progress as data from these trials are beginning to be presented at prestigious conferences such as ASH,” said Susan Molineaux, PhD,...

THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER OR AN INVITATION TO ACQUIRE OR DISPOSE OF ANY SECURITIES. YOUR ATTENTION IS ALSO DRAWN TO THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.Summit Therapeutics plc(“Summit”, or the “Company”)Summit Announces a Proposed Subscription and Placing to Raise approximately $50.0 Million and Notice of General MeetingOxford, UK, and Cambridge, MA, US, 6 December 2019 – Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces a...

SANTA MONICA, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) — GBT Technologies Inc. (OTC PINK: GTCH) (“GBT”, or the “Company”), a company specializing in the development of Internet of Things (IoT) and Artificial Intelligence (AI) enabled networking and tracking technologies, including its GopherInsight™ wireless mesh network technology platform and its Avant! AI, for both mobile and fixed solutions aimed at expanding AI market opportunities, announced today it will deploy its Avant! AI into the field of Sports Handicapping.Sports Handicapping is used in scoring many games and competitive sports, and refers to the various methods by which spectators may predict and quantify the results of a sporting match. The term is applied to the practice of predicting the result of a competition, such as for purposes of betting against the point...

MALVERN, Pa., Dec. 06, 2019 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company has signed a group purchasing agreement with HealthTrust Purchasing Group, L.P. (HealthTrust) for its full portfolio of OviTex® hernia repair and OviTex® PRS products.“We are excited to be able to provide our advanced soft tissue reconstruction products to the HealthTrust member facilities, which represents more than 1,600 hospitals and health systems across the U.S.,” said Antony Koblish, President and Chief Executive Officer of TELA Bio. “Making our full portfolio of products available to such a large organization of...

EWING, N.J., Dec. 06, 2019 (GLOBE NEWSWIRE) — Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”) today announced that the Company’s social media campaign for XYOSTED®, has been honored with a 2019 MarCom Platinum Award.  The award is the highest level achievable in the international marketing competition.The social media campaign for XYOSTED® featured a series of Facebook and Instagram ads to prime existing testosterone deficient patients for the launch of a new testosterone replacement therapy. The ads used humor and arresting imagery which focused on the challenges of other testosterone therapies such as messy application of testosterone gels and painful intramuscular injections.  XYOSTED® is a once weekly, virtually painless subcutaneous injection of testosterone which can restore men’s testosterone levels into the...

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) — Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the presentation of data at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) in Los Angeles (December 4-7, 2019) on AT-001, a novel, potent and selective aldose reductase inhibitor (ARI) in Phase 3 clinical development for Diabetic Cardiomyopathy (DbCM).“The Aldose Reductase enzyme has long been known to play a key role in several diabetic complications, including DbCM,” said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics. “Unfortunately, past attempts to inhibit Aldose Reductase failed...

NEW YORK, Dec. 06, 2019 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, highlighted three upcoming ELZONRIS (tagraxofusp), presentations, including an oral presentation of ELZONRIS clinical data in myelofibrosis, at this year’s American Society of Hematology (ASH) Annual Meeting and Exposition, that is being held from December 7-10 in Orlando, FL.Details on the ASH presentations are as follows:About ELZONRIS® ELZONRIS® (tagraxofusp-erzs), a CD123-directed cytotoxin, is approved by the U.S. Food and Drug Administration (FDA) and commercially available in the U.S. for the treatment of adult and pediatric patients, two years or older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN)....